<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029609</url>
  </required_header>
  <id_info>
    <org_study_id>TILS-015</org_study_id>
    <nct_id>NCT05029609</nct_id>
  </id_info>
  <brief_title>Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS</brief_title>
  <official_title>A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tiziana Life Sciences, PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tiziana Life Sciences, PLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to establish the safety of administration of intranasal Foralumab in&#xD;
      non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple&#xD;
      ascending dose format in escalating doses for 14 consecutive days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study&#xD;
      evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients&#xD;
      with MS.&#xD;
&#xD;
      Up to 55 untreated primary and secondary progressive MS patients will be enrolled, to obtain&#xD;
      a total of 48 completed subjects (9 active, 3 placebos per group), allowing for dropouts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients with MS.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the safety of intranasal foralumab in non-active primary and secondary progressive MS in escalating doses for 14 consecutive days</measure>
    <time_frame>14 days</time_frame>
    <description>Analyses through review of adverse events categorized and graded via CTCAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Expanded Disability Status Scale (EDSS) at Day 45</measure>
    <time_frame>45 days</time_frame>
    <description>The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. EDSS steps 1.0 to 4.5 refer to people with MS who are able to walk without any aid and is based on measures of impairment in eight functional systems. Lower score indicates that the subject is doing better.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group A will receive nasal Foralumab Dose 1 daily for 14 days (n=9) or placebo (n=3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group B will receive nasal Foralumab Dose 2 tiw for 14 days (n=9) or placebo (n=3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group C will receive nasal Foralumab Dose 3 daily for 14 days (n=9) or placebo (n=3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group D will receive nasal Foralumab Dose 4 daily for 14 days (n=9) or placebo (n=3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Foralumab Solution</intervention_name>
    <description>The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of MS (according to the 2010 McDonald criteria).&#xD;
&#xD;
          2. Age 25-70 years.&#xD;
&#xD;
          3. Clinical diagnosis of non-active primary and secondary MS&#xD;
&#xD;
          4. MRI imaging consistent with a diagnosis of MS at any time point.&#xD;
&#xD;
          5. Score on the Expanded Disability Status Scale (EDSS) of 2.5-6.5&#xD;
&#xD;
          6. Adequate hematologic parameters without ongoing transfusion support:&#xD;
&#xD;
               -  Hemoglobin (Hb) ≥ 9 g/dL&#xD;
&#xD;
               -  Platelets ≥ 100 x 109 cells/L&#xD;
&#xD;
          7. Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance&#xD;
&#xD;
             ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula&#xD;
&#xD;
          8. Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's&#xD;
             disease&#xD;
&#xD;
          9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN,&#xD;
             or &lt; 5 times ULN for patients with liver metastases&#xD;
&#xD;
         10. QT interval corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on&#xD;
             the ECG obtained at Screening&#xD;
&#xD;
         11. Negative serum pregnancy test within 14 days prior to the first dose of study therapy&#xD;
             for women of child-bearing potential (WCBP)&#xD;
&#xD;
        13. Ability to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Corticosteroid use (oral or intravenous) within the last 30 days.&#xD;
&#xD;
          2. Current use or use in the prior 6 months of MS immunotherapy, interferon, glatiramer&#xD;
             acetate, fingolimod, siponimod, dimethyl fumarate or natalizumab or any other chronic&#xD;
             immunosuppressive medication&#xD;
&#xD;
          3. Inability to tolerate intranasally administered medications&#xD;
&#xD;
          4. Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days.&#xD;
&#xD;
          5. Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within&#xD;
             the past 12 months.&#xD;
&#xD;
          6. Active COVID-19 disease; according to FDA guidelines&#xD;
&#xD;
          7. Female patient who is pregnant, lactating, breastfeeding, or planning on becoming&#xD;
             pregnant during study.&#xD;
&#xD;
          8. Female patients of childbearing age will undergo a pregnancy test and be excluded from&#xD;
             the study if positive.&#xD;
&#xD;
          9. Active malignancy within 5 years.&#xD;
&#xD;
         10. Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus,&#xD;
             asthma, or type 1 diabetes&#xD;
&#xD;
         11. Neutropenia (&lt;500 neutrophils/mL) or other severe immunosuppression&#xD;
&#xD;
         12. Unable or unwilling to comply with protocol requirements.&#xD;
&#xD;
         13. Patients with a history of gadolinium allergy.&#xD;
&#xD;
         14. Screening labs outside of the normal range; EBV IgM positive subjects with clinical&#xD;
             signs will not receive study drug.&#xD;
&#xD;
         15. Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia,&#xD;
             myocardial infarction, unstable angina or heart disease defined by the New York Heart&#xD;
             Association (NYHA) Class III or Class IV (See Appendix B) or hereditary long QT&#xD;
             syndrome&#xD;
&#xD;
         16. Concomitant medication(s) that may cause QTc prolongation or induce Torsades de&#xD;
             Pointes, except for antimicrobials that are used as standard of care to prevent or&#xD;
             treat infections and other such drugs that are considered by the Investigator to be&#xD;
             essential for patient care&#xD;
&#xD;
         17. Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface&#xD;
             antigen (HBsAg) or hepatitis C virus (HCV)&#xD;
&#xD;
         18. Any other medical intervention or other condition which, in the opinion of the&#xD;
             Principal Investigator, could compromise adherence to study requirements or confound&#xD;
             the interpretation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Venkat S Renukuntla, MBBS, MPH</last_name>
    <phone>+1267-810-9994</phone>
    <email>vrenukuntla@tizianalifesciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vaseem Palejwala, Phd</last_name>
    <email>vpalejwala@tizianalifesciences.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

